武汉禾元生物科技股份有限公司 2025年度业绩快报公告

Financial Data Summary - The company reported total revenue of 47.86 million RMB for the year 2025, representing a year-on-year increase of 89.80% [1][2] - The net loss attributable to the parent company was 157.94 million RMB, an increase in loss of 6.58 million RMB compared to the previous year [1][3] - The total assets at the end of the reporting period were 3.70 billion RMB, an increase of 248.65% from the beginning of the period [1][3] - The equity attributable to the parent company was 2.90 billion RMB, reflecting a growth of 381.75% [1][3] Operational Performance - The significant increase in total revenue was primarily driven by the rapid sales breakthrough of the new product "Aofumin," which was approved for market launch in July 2025 [2][3] - Continuous investment in research and development has been maintained to support the ongoing output of research results [2] Key Changes in Financial Metrics - The company's total assets, equity attributable to the parent company, share capital, and net asset value per share increased by 248.65%, 381.75%, 33.37%, and 261.61% respectively, mainly due to the funds raised from the initial public offering [3]